Antidotes to factor XA inhibitors

US12195774B2 · kind B2 · utility

Assignee

• Alexion Pharmaceuticals, Inc. · US

Inventors

• Pamela B. Conley · Palo Alto, US
• Genmin Lu · South San Francisco, US
• Leonard G. Presta · San Francisco, US
• John T. Curnutte · Hillsborough, US

Key dates

• Filing date: Jun 18, 2019
• Grant date: Jan 14, 2025
• Expiry date: Oct 12, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y304/21006
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. In one embodiment, the derivatives described herein lack or have reduced intrinsic coagulant activity.